Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

समान संसाधन

• Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  द्वारा: Nigel Bundred (15046233)
  प्रकाशित: (2025)
• Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  द्वारा: Nigel Bundred (15046233)
  प्रकाशित: (2025)
• Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  द्वारा: Nigel Bundred (15046233)
  प्रकाशित: (2025)
• Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
  द्वारा: Nigel Bundred (15046233)
  प्रकाशित: (2025)
• Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
  द्वारा: Ruiyun Zhang (17142498)
  प्रकाशित: (2025)